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ABSTRACT: Nitrile-type inhibitors are known to interact
with cysteine proteases in a covalent-reversible manner. The
chemotype of 3-cyano-3-aza-β-amino acid derivatives was
designed in which the N-cyano group is centrally arranged in
the molecule to allow for interactions with the nonprimed and
primed binding regions of the target enzymes. These
compounds were evaluated as inhibitors of the human cysteine
cathepsins K, S, B, and L. They exhibited slow-binding
behavior and were found to be exceptionally potent, in particular toward cathepsin K, with second-order rate constants up to
52 900 × 103 M−1 s−1.
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Cysteine cathepsins, proteolytic enzymes located within thelysosomes, belong to the family of papain-like cysteine
peptidases. The overexpression of theses enzymes has been
implicated in a multitude of pathological conditions, such as
tumor progression and metastasis, MHC class II antigen
presentation, and bone remodeling.1,2 The cysteine protease
cathepsin K degrades several components of the bone matrix and
has emerged as a promising target for intervention by small
molecules on the basis of the inhibition of osteoclastic resorption
observed in human and knockout animal models. Several
cathepsin K inhibitors have been developed to reduce the
excessive bone matrix degradation associated with osteoporosis.
Among them, the front-runner odanacatib (1, Figure 1), a
nonbasic and nonlysosomotropic peptidomimetic nitrile, is
currently being developed as a once weekly treatment for
osteoporosis.3−6
Odanacatib (1) exhibits characteristic features of low
molecular weight inhibitors of cysteine cathepsins, which are
mainly peptidomimetic structures containing an electrophilic
warhead to allow for covalent interactions with the active-site
cysteine. Among such inhibitors, dipeptide nitriles have attracted
particular attention. In the course of the drug development, a
dipeptide has typically been decorated with an N-terminal
capping group and the carboxylic function has been replaced by a
cyano group. The P2 and P1 amino acid side chains then allow
for speciﬁc binding to the S2 and S1 pockets within the active site
of the target enzymes, the capping group for an interaction with
the S3 binding pocket. The reaction of dipeptide nitriles with
cysteine proteases involves the nucleophilic attack of the thiolate
moiety at the inhibitors’ nitrile carbon and thus the reversible
formation of thioimidate adducts.7
For papain-like cysteine proteases, azadipeptide nitriles have
been introduced as a new inhibitor class whose representatives
exhibitedKi values toward human cysteine cathepsins in the nano
and even picomolar range. Such inhibitors have been designed
through an exchange of the α-CH moiety of the P1 amino nitrile
by a nitrogen atom.8,9 Azadipeptide nitriles form covalent-
reversible isothiosemicarbazide adducts upon being attacked by
the active site cysteine nucleophile. Representative examples for
azadipeptide nitriles are depicted in Figure 1. The nitrogen atoms
of the aza-amino nitrile moiety of azadipeptide nitriles are
essentially alkylated for reasons of synthetic access. Undesired
cyclization reactions have been observed when the nitrogen of
the P2−P1 peptide bond and/or the P1 α-nitrogen bear a
hydrogen substituent (−CO−NH−NH−CN, −CO−NH−
NR−CN, or −CO−NR−NH−CN).8 However, carbamate-
protected aza-amino nitriles have been described as cathepsin
K inhibitors, which contain the open-chain O−CO−NH−NR−
CN motif.12
A systematic scan with respect to the P3 and P2 substituents
was performed to elucidate the strong impact of the noncovalent
interactions for cathepsin K inhibition by azadipeptide
nitriles.13,14 The high electrophilic reactivity15 toward thiols is
not a suﬃcient condition for cathepsin inhibition, as, for example,
Gly in P2 position in place of a preferred amino acid reduced the
potency by 3 orders of magnitude.13 The sulfone derivative 3
showed dual inhibition of human cathepsins S and K with
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picomolar Ki values.
16 In further series of azadipeptide nitriles,
leucine was maintained at P2 position, and several aryl moieties
were introduced in the N-terminal amide portion;17 a direct
linkage of these aryl groups to the α-carbon of the P2 building
block caused a strong reduction of the aﬃnity to cathepsin K.18
The azadipeptide nitrile chemotype was employed for the design
of activity-based probes for in situ proteome proﬁling of
Trypanosoma brucei19 and was chemically converted into
ﬂuorescent derivatives to be used for cathepsin labeling.20 The
ﬂuorine-18 labeled inhibitor 4 was applied for positron emission
tomography to image tumor-associated cathepsin activity.21
Moreover, a cathepsin inhibitor cargo was linked by click
chemistry to the localization peptide Tat for organelle-speciﬁc
targeting, and subcellular delivery of the inhibitor-Tat conjugate
5 to the lysosomes was reported.22
In the present study we aimed at synthesizing cysteine
protease inhibitors with an N-cyano group, which is centrally
arranged in the molecule. This group was expected to interact
with the active site cysteine and the ﬂanking parts with the
nonprimed and primed subsites of the target protease. Such type
of nitrile-based inhibitors has not been described so far and can
be considered as a structural expansion of cathepsin inhibiting
alkyl 2-cyano-2-methylhydrazinecarboxylates.12 It was intended
to introduce the cyano group via electrophilic cyanation.23
Incorporation of an aza-α-amino acid would lead to a −CO−
NH−NαH−CO− substructure, in which the α-nitrogen would
not be susceptible to electrophilic cyanation. Therefore, we
envisaged a 3-aza-β-amino acid as the core element of the desired
compounds. The corresponding −CO−NH−NβH−CαH2−
CO− substructure should then allow the preparation of the 3-
cyano-3-aza-β-amino acid derivatives.
The synthesis of the ﬁnal compounds is illustrated in Scheme
1. Condensation of the carbazates 6 and 7 with glyoxylic acid
gave the hydrazones 8 and 9. Amide coupling of 8 and 9 with
morpholine, N-benzylmethylamine, and N,N-dibenzylamine,
Figure 1. Peptidomimetic cathepsin inhibitors: structures of the
cathepsin K inhibitors odanacatib (1) and balicatib (2) and of
azadipeptide nitriles.
Scheme 1. Synthesis of 3-Cyano-3-aza-β-amino Acid
Derivatives 22−27a
aReagents and conditions: (a) glyoxylic acid monohydrate, EtOH, RT;
(b) (i) ClCO2i-Bu, NMM, THF, −25 °C; (ii) HNR2R3, THF, −25 °C
to RT; (c) H2, Pd/C (10%), MeOH, 3.3 bar, RT; (d) BrCN, NaOAc,
MeOH, RT.
Scheme 2. Alternative Synthesis of the 3-Aza-β-amino Acid
Derivative 19a
aReagents and conditions: (a) H2, Pd/C (10%), MeOH, 3.3 bar, RT;
(b) (i) ClCO2i-Bu, NMM, THF, −25 °C; (ii) morpholine, THF, −25
°C to RT.
Chart 1. Atropisomeric Structures of Azadipeptides 30 and 31
Chart 2. Mesomeric Structures of the EConﬁgured Hydrazide
and Carbazate Fragments of 30, 31, and 25−27
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respectively, furnished 10−15. These compounds were catalyti-
cally hydrogenated to hydrazinoacetic acid derivatives 16−21 in
order to make the β-nitrogen accessible to cyanation. Reactions
with cyanogen bromide produced the Boc-protected ﬁnal
compounds 22−27. At the C-terminus, this ﬁrst series of 3-
cyano-3-aza-β-amino acid derivatives contains a tertiary carbox-
amide moiety. Whether it would also be possible to exchange R2
and/or R3 by hydrogen without eliciting a concomitant
cyclization was not examined in the course of this study.
An alternative order of reactions was followed as outlined in
Scheme 2. Starting with 9, the hydrogenation step was carried out
prior to the amide coupling. Indeed, we obtained 29 and
successively 19, the precursor to the ﬁnal product 25. However,
when applying the hydrogenation-coupling sequence to the
demethylated analogue 8 and then obtaining 28, the subsequent
coupling reaction with morpholine failed.
Concerning the structural elucidation we have initially paid
attention to the intermediates 10−15. Signals for two isomers
occurred in the 1H and 13C NMR spectra of the N-
benzylmethylamino derivatives 11 and 14. This could result
from two diﬀerent functionalities. E/Z isomerism is possible (i)
because of the CN double bond or (ii) because of the partial
double bond character of the CCO−N bond. A corresponding
E/Z isomerism about the carbamate OCO−N bond was ruled
out as this would only be valid in the case of 14. Thus, the amide
bond in 11 and 14 was suspected to be responsible for the
mixtures. This was also based on the ﬁndings that (i)
hydrogenation to 17 and 20 did not lead to a disappearance of
mixtures and (ii) suchmixtures have neither been observed in the
case of the morpholine-derived intermediates 10 and 13 and
hydrazinoacetic acid derivatives 16 and 19 nor in case of the N-
dibenzylamine-derived intermediates 12 and 15 and hydrazino-
acetic acid derivatives 18 and 21. Hence, the appearance of the
isomers resulted from the E/Z isomerism about the amide bond
in the unequally substituted tertiary carboxamides 11, 14, 17, and
Table 1. Kinetic Parameters of Inhibition of Cathepsins by 3-Cyano-3-aza-β-amino Acid Derivatives 22−25 and Balicatib
aIC50 values were obtained from duplicate measurements in the presence of ﬁve diﬀerent inhibitor concentrations. IC50 values were determined by
nonlinear regression using equation vs = v0/(1 + [I]/IC50), were vs is the steady-state rate, v0 is the rate in the absence of the inhibitor, and [I] is the
inhibitor concentration. Ki values were calculated from IC50 values by applying the equation Ki = IC50/(1 + [S]/Km), where [S] is the substrate
concentration. bThe cathepsin K assay was performed with the ﬂuorogenic substrate Z-Leu-Arg-AMC at a ﬁnal concentration of 40 μM (13.3 × Km).
The reaction was followed over 60 min.13 cThe cathepsin S assay was performed with the ﬂuorogenic substrate Z-Phe-Arg-AMC at a ﬁnal
concentration of 40 μM (0.74 × Km). The reaction was followed over 60 min.
38 dThe cathepsin B assay was performed with the chromogenic
substrate Z-Arg-Arg-pNA at a ﬁnal concentration of 500 μM (0.45 × Km). The reaction was followed over 30 min.
13 eThe cathepsin L assay was
performed with the chromogenic substrate Z-Phe-Arg-pNA at a ﬁnal concentration of 100 μM (5.88 × Km). The reaction was followed over 30
min.13 fProgress curves were analyzed by nonlinear regression using the slow-binding equation [P] = vst + (vi − vs)(1 − exp(−kobst))/(kobs + d) to
give vs, vi, and kobs, where [P] is the product concentration, vi is the initial rate, kobs is the observed ﬁrst-order rate constant, and d is the oﬀset. To
obtain IC50 values, vs values from reactions in the presence of the inhibitor and v0 values obtained by linear regression of the progress curves in the
absence of the inhibitor were used. The second-order rate constants kon were obtained by linear regression according to equation kobs = kon[I]/(1 +
[S]/Km) + koff, where koff is the ﬁrst-order rate constant of dissociation.
gProgress curves were analyzed by linear regression after steady-state was
reached (5−30 min). hThe reaction was followed over 20 min, and progress curves were analyzed by linear regression. For literature IC50 values and
corresponding assay conditions, see refs 39 and 40.
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20; it was also observed in the corresponding ﬁnal products 23
and 26.
In previous studies, it has been shown that the azadipeptide
amide 30 forms atropisomers (Chart 1).32,33 The diastereotopic
protons of the glycine fragment indicated a restricted rotation
around the N−N single bond. This rotation was enforced with a
variable temperature (VT) NMR experiment, and a value of 117
kJ/mol was determined for the rotational barrier. As
atropisomers have rotational barriers higher than 95 kJ/mol,
compound 30 exhibits chirality as a result of its atropisomer-
ism.32 Moreover, the azadipeptide nitrile 31 showed diastereo-
topic glycine methylene protons13 and is structurally similar to
the ﬁnal compounds 25−27 of this study. Therefore, we
addressed the question whether 25−27 would also form
atropisomers. However, diastereotopic protons in the cor-
responding 1H NMR spectra were not observed. For example,
in the 1H NMR spectrum of 27, three distinct singlets for the
methylene protons appear. It could therefore be concluded that
in 25−27 a free rotation around the N−N single bond is possible.
With respect to such a bond rotation, the signiﬁcant diﬀerence
between the azadipeptides 30 and 31, on the one hand, and the 3-
cyano-3-aza-β-amino acid derivatives 25−27, on the other hand,
is the position next to the N−N−CO carbonyl group. In
comparison to the methylene group (in 30 and 31), the oxygen
atom (in 25−27) is less voluminous. Moreover, it is the
methylation of the peptide bond in azadipeptides 30 and 31 that
leads to the E conﬁguration (Chart 2) and hence to the
aforementioned atropisomerism.32 In 3-cyano-3-aza-β-amino
acid derivatives 25−27, one more mesomeric structure is
possible and the contribution of the third limiting structure to
the resonance reduces the double bond character of the CO−N
bond (Chart 2).34−36 Thus, the E conﬁguration in 25−27 is
supposed to be less deﬁned, and consequently, the N−N single
bond rotation is not hindered.
The results of the biochemical evaluation of 22−25 and, for
comparison purpose, balicatib at four human cysteine cathepsins
are outlined in Table 1. Fluorogenic or chromogenic peptide
substrates were employed in the activity assays. Our inhibitors
showed time-dependent inhibition of the target cathepsins. This
behavior was in agreement with the expected covalent and
reversible enzyme−inhibitor interaction. In some cases, the
progress curves were analyzed after achievement of steady-state
by linear regression. Plots of the steady-state rates versus
inhibitor concentration gave IC50 values. Assuming an active-site
directed mode of action, those were corrected using the Cheng−
Prusoﬀ equation to obtain the true inhibition constants, Ki. In
other cases, the progress curves were analyzed by means of the
slow binding equation,37 and nonlinear regression analysis of the
progress curves provided the ﬁrst-order rate constants kobs,
besides the steady-state rates. The kobs values were used to obtain
second-order rate constants, kon, governing the enzyme−
inhibitor association. As Ki values were also determined as
noted above, ﬁrst-order rate constants for the dissociation of the
enzyme−inhibitor complex, koff, were also accessible (Ki = koff/
kon). A representative kinetic analysis is illustrated in Figure 2.
As a ﬁrst result of the kinetic investigations, a major diﬀerence
in the inhibitory potency of the nonmethylated and the
methylated morpholine derivatives was ascertained (22 versus
25), which was particularly striking in the case of cathepsin K (Ki
of 11 pM versus Ki of 31 nM). It has been described that a
nonmethylated amide bond in nitrile-type cysteine protease
inhibitors (−CO−NH−X−CN) resulted in a much stronger
inhibition than the methylated analogues (−CO−NMe−X−
CN).8,12
Thus, we focused on the three nonmethylated 3-cyano-3-aza-
β-amino acid derivatives (22−24) to elucidate structure−activity
relationships. Noteworthy, these three derivatives exhibited a
gradual decrease in aﬃnity toward cathepsins K, S, B, and L. The
stepwise introduction of one or two bulky aromatic moieties
resulted in an improved inhibitory potency (22 versus 23 versus
24), which was determined for the four enzymes. Obviously, the
benzyl groups allow for hydrophobic or cation−π interactions
with the cathepsins’ active sites.
For human cathepsins K and S, inhibitors 22−24 exhibited
very low Ki values down to 1.43 pM (24 at cathepsin K). This
strong aﬃnity is mainly due to an accelerated association to form
the enzyme−inhibitor complex(es), as it can be inferred from the
high second-order rate constants (e.g., kon = 52 900 × 10
3 M−1
s−1 for 24 at cathepsin K). For 22−24, half-lives of the cathepsin
K-inhibitor and cathepsin S-inhibitor complexes could be
calculated from the corresponding koff values and were in the
range between 10 and 150 min (22 at cathepsin S and 24 at
cathepsin K).
Figure 2. Inhibition of human cathepsin K by 22. Top: Monitoring of
the cathepsin K-catalyzed hydrolysis of Z-Leu-Arg-AMC in the presence
of increasing concentrations of compound 22 (closed circles, 0 pM;
open circles, 400 pM; closed squares, 800 pM; open squares, 1200 pM;
closed triangles, 1600 pM; open triangles, 2000 pM). Fluorescence
emission at 440 nm was measured after excitation at 360 nm. Bottom:
Plot of the rates obtained in duplicate measurements versus
concentrations of 22. Nonlinear regression gave an IC50 value of 158
(±14) pM. Inset: Plot of the ﬁrst-order rate constants kobs versus
concentrations of 22. Linear regression gave a value kon/(1 + [S]/Km) of
1.33 (±0.15) × 10−6 pM−1 s−1.
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We propose that the Boc capping group of the 3-cyano-3-aza-
β-amino acid derivatives is bound in the nonprimed binding
region of the target enzymes and that the amide part is
accommodated in the primed binding region. This assumption is
based on the cocrystal structure of tert-butyl 2-cyano-2-
methylhydrazinecarboxylate with cathepsin K.12 In this complex,
the tert-butyl group occupies the S2 pocket formed by residues
67Tyr, 68 Met, 134Ala, 163Ala, and 209Leu. Hydrogen bonding
interactions of the carbamate occur with the backbone NH of
66Gly and the backbone carbonyl oxygen of 161Asn.12 Although
alkyl 2-cyano-2-methylhydrazinecarboxylates exhibit a pro-
nounced cathepsin K inhibition, the cathepsin K selectivity of
the inhibitors described herein is even stronger and is probably
caused by hydrophobic or cation−π interactions with the
nonprimed binding region of cathepsin K. In future studies, it
is intended to expand the inhibitor structure to both directions.
This will enable to better deﬁne the binding mode of this new
type of cysteine protease inhibitors. On the one hand, prior to
cyanation and hydrogenation, a Boc-deprotection would allow
for the incorporation of moieties to interact with the S1 and S2
pockets. On the other hand, the introduction of amino acid
derivatives, in place of the secondary amines used in this study,
might direct the so-modiﬁed amide part to the S1′ and S2′
pockets.
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based inhibitors of cysteine cathepsins. Bioorg. Med. Chem. Lett. 2012,
22, 7715−7718.
ACS Medicinal Chemistry Letters Featured Letter
dx.doi.org/10.1021/ml500238q | ACS Med. Chem. Lett. 2014, 5, 1076−10811080
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